178 related articles for article (PubMed ID: 19232039)
1. Nebulized formoterol effect on bronchodilation and satisfaction in COPD patients compared to QID ipratropium/albuterol MDI.
Sutherland ER; Brazinsky S; Feldman G; McGinty J; Tomlinson L; Denis-Mize K
Curr Med Res Opin; 2009 Mar; 25(3):653-61. PubMed ID: 19232039
[TBL] [Abstract][Full Text] [Related]
2. Nebulized formoterol provides added benefits to tiotropium treatment in chronic obstructive pulmonary disease.
Tashkin DP; Hanania NA; McGinty J; Denis-Mize K; Chaudry I
Adv Ther; 2009 Nov; 26(11):1024-34. PubMed ID: 19953349
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of formoterol fumarate delivered by nebulization to COPD patients.
Gross NJ; Nelson HS; Lapidus RJ; Dunn L; Lynn L; Rinehart M; Denis-Mize K;
Respir Med; 2008 Feb; 102(2):189-97. PubMed ID: 18363201
[TBL] [Abstract][Full Text] [Related]
4. Daily variation in lung function in COPD patients with combined albuterol and ipratropium: results from a 4-week, randomized, crossover study.
Singh D; Zhu CQ; Sharma S; Church A; Kalberg CJ
Pulm Pharmacol Ther; 2015 Apr; 31():85-91. PubMed ID: 25197005
[TBL] [Abstract][Full Text] [Related]
5. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial.
Tashkin DP; Littner M; Andrews CP; Tomlinson L; Rinehart M; Denis-Mize K
Respir Med; 2008 Apr; 102(4):479-87. PubMed ID: 18258423
[TBL] [Abstract][Full Text] [Related]
6. Nebulized formoterol fumarate: Dose selection and pharmacokinetics.
Gross NJ; Kerwin E; Levine B; Kim KT; Denis-Mize K; Hamzavi M; Carpenter M; Rinehart M
Pulm Pharmacol Ther; 2008 Oct; 21(5):818-23. PubMed ID: 18655841
[TBL] [Abstract][Full Text] [Related]
7. Long-term safety and efficacy of formoterol fumarate inhalation solution in patients with moderate-to-severe COPD.
Hanania NA; Sethi S; Koltun A; Ward JK; Spanton J; Ng D
Int J Chron Obstruct Pulmon Dis; 2019; 14():117-127. PubMed ID: 30643398
[TBL] [Abstract][Full Text] [Related]
8. Bronchodilation and safety of supratherapeutic doses of salbutamol or ipratropium bromide added to single dose GSK961081 in patients with moderate to severe COPD.
Norris V; Ambery C
Pulm Pharmacol Ther; 2013 Oct; 26(5):574-80. PubMed ID: 23524017
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of ipratropium bromide/albuterol compared with albuterol in patients with moderate-to-severe asthma: a randomized controlled trial.
Donohue JF; Wise R; Busse WW; Garfinkel S; Zubek VB; Ghafouri M; Manuel RC; Schlenker-Herceg R; Bleecker ER
BMC Pulm Med; 2016 Apr; 16(1):65. PubMed ID: 27130202
[TBL] [Abstract][Full Text] [Related]
10. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
[TBL] [Abstract][Full Text] [Related]
11. Formoterol as dry powder oral inhalation compared with salbutamol metered-dose inhaler in acute exacerbations of chronic obstructive pulmonary disease.
Cazzola M; D'Amato M; Califano C; Di Perna F; Calderaro E; Matera MG; D'Amato G
Clin Ther; 2002 Apr; 24(4):595-604. PubMed ID: 12017404
[TBL] [Abstract][Full Text] [Related]
12. Formoterol: a review of its use in chronic obstructive pulmonary disease.
Cheer SM; Scott LJ
Am J Respir Med; 2002; 1(4):285-300. PubMed ID: 14720051
[TBL] [Abstract][Full Text] [Related]
13. A double-blind crossover study comparing the safety and efficacy of three weeks of Flu/Sal 250/50 bid plus albuterol 180 ug prn q4 hours to Flu/Sal 250/50 bid plus albuterol/Ipratropium bromide 2 puffs prn q4 hours in patients with chronic obstructive pulmonary disease.
Balkissoon R; Make B
COPD; 2008 Aug; 5(4):221-7. PubMed ID: 18671147
[TBL] [Abstract][Full Text] [Related]
14. COPD patient satisfaction with ipratropium bromide/albuterol delivered via Respimat: a randomized, controlled study.
Ferguson GT; Ghafouri M; Dai L; Dunn LJ
Int J Chron Obstruct Pulmon Dis; 2013; 8():139-50. PubMed ID: 23658479
[TBL] [Abstract][Full Text] [Related]
15. Long-term safety of nebulized formoterol: results of a twelve-month open-label clinical trial.
Donohue JF; Hanania NA; Fogarty C; Campbell SC; Rinehart M; Denis-Mize K
Ther Adv Respir Dis; 2008 Aug; 2(4):199-208. PubMed ID: 19124372
[TBL] [Abstract][Full Text] [Related]
16. An evaluation of inhaled bronchodilator therapy in patients hospitalized for non-life-threatening COPD exacerbations.
Woods JA; Usery JB; Self TH; Finch CK
South Med J; 2011 Nov; 104(11):742-5. PubMed ID: 22024782
[TBL] [Abstract][Full Text] [Related]
17. Long-acting dual bronchodilator therapy (indacaterol/glycopyrronium) versus nebulized short-acting dual bronchodilator (salbutamol/ipratropium) in chronic obstructive pulmonary disease: A double-blind, randomized, placebo-controlled trial.
van Geffen WH; Carpaij OA; Westbroek LF; Seigers D; Niemeijer A; Vonk JM; Kerstjens HAM
Respir Med; 2020 Sep; 171():106064. PubMed ID: 32917359
[TBL] [Abstract][Full Text] [Related]
18. An economic assessment of inhaled formoterol dry powder versus ipratropium bromide pressurized metered dose inhaler in the treatment of chronic obstructive pulmonary disease.
Hogan TJ; Geddes R; Gonzalez ER
Clin Ther; 2003 Jan; 25(1):285-97. PubMed ID: 12637127
[TBL] [Abstract][Full Text] [Related]
19. Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease.
Appleton S; Jones T; Poole P; Pilotto L; Adams R; Lasserson TJ; Smith B; Muhammad J
Cochrane Database Syst Rev; 2006 Jul; 2006(3):CD006101. PubMed ID: 16856113
[TBL] [Abstract][Full Text] [Related]
20. In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium : a 3-week, randomized, double-blind, within-patient, multicenter study.
D'Urzo AD; De Salvo MC; Ramirez-Rivera A; Almeida J; Sichletidis L; Rapatz G; Kottakis J;
Chest; 2001 May; 119(5):1347-56. PubMed ID: 11348938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]